Pancreatic Cancer Diagnosis
Pancreatic Cancer Diagnosis
Diagnosis of pancreatic cancer is a sequence of questions, and the order matters: is there a mass, is it removable, and what is it made of. The right scan answers the first two; a needle answers the third.
CT first, and why the protocol matters
The first-line test is a multiphase contrast-enhanced CT of the pancreas, and the word protocol is what makes it useful. A routine abdominal scan taken in one phase will show a mass, but it will not reliably show whether that mass is separable from the superior mesenteric artery — and that single question decides whether surgery is on the table.
A pancreatic protocol study images the gland in thin slices during the phases when arterial and venous anatomy are clearest, and it is reported with the vessels specifically described. When a CT is equivocal, or when a patient cannot have iodinated contrast, MRI with MRCP is the alternative: it characterises small liver lesions better and shows the ducts without contrast, which is useful when a stent is already in place.
- What CT answers — is there a pancreatic mass; does it touch, abut or encase the artery; is the vein involved; are there liver or peritoneal deposits; is the bile duct dilated.
- What MRI adds — indeterminate liver lesions, small cystic lesions, and ductal anatomy without contrast.
- What neither can do — tell you the cell type. A scan describes anatomy, not biology.
This is why sending pictures rather than a report matters so much for a second opinion. Resectability is decided by looking at the images, and a report that says "mass in the pancreas with vascular contact" does not contain the information a surgeon needs to say whether it is operable.
Endoscopic ultrasound and the tissue diagnosis
Endoscopic ultrasound places a small ultrasound probe in the stomach and duodenum, a few millimetres from the pancreas, and it can do two things at once: describe the tumour and the nodes in detail, and pass a needle through the gut wall to obtain cells or tissue. That combination is why it is the standard route to a diagnosis.
- Fine-needle aspiration gives cells for cytology and is the usual choice when a diagnosis needs to be confirmed before chemotherapy.
- Fine-needle biopsy takes a core of tissue, which allows architecture to be assessed and yields more material for molecular testing — relevant when a KRAS variant, a BRCA alteration or mismatch repair status will influence treatment.
- Timing — if the tumour is going straight to surgery, some centres operate without a pre-operative needle, because the diagnosis will be made on the resected specimen. If chemotherapy is planned first, a tissue diagnosis is required before it starts.
Two practical caveats are worth knowing. A negative biopsy does not exclude cancer, because the needle can miss; the imaging findings then carry the decision. And if the tumour is unresectable, the tissue diagnosis is not optional — systemic treatment should not begin on the basis of imaging alone.
CA19-9: what the marker can and cannot do
CA19-9 is a carbohydrate antigen shed by pancreatic and biliary cells. It is measured from a blood sample, it is cheap, and it is the marker most often ordered — and it is also the most often misunderstood.
- It can be normal in cancer. People who are Lewis-antigen negative — roughly one in twenty — do not produce it at all, however advanced the tumour.
- It rises without cancer. Any obstruction of the bile duct raises it: gallstones, cholangitis, and a stent that has just been placed. A level taken during jaundice has to be interpreted with that in mind.
- It is not a screening test. A normal value does not exclude the disease, and it is not recommended for screening people without symptoms.
- Its trend is more useful than its value. A baseline before treatment, then measurements afterwards, tell you whether the treatment is working; a single number tells you very little.
The correct use of CA19-9 in pancreatic cancer is therefore as a baseline and a trend marker: measured before surgery or chemotherapy, repeated at defined points, and read together with imaging. If the level falls while on treatment and rises later, that is a signal to restage even before symptoms return.
Staging: what the tests are looking for
Staging pancreatic cancer means answering four questions, and each is answered by a different part of the work-up:
- How deep is the tumour, and does it reach beyond the gland? Answered by the pancreatic protocol CT, and refined by endoscopic ultrasound for small tumours.
- Are the regional nodes involved? Answered by CT and EUS; node staging is less accurate than in some other cancers, which is one reason surgery is not abandoned on the basis of a single enlarged node.
- Is there distant spread? The liver is the commonest site, then the peritoneum and the lungs. CT covers most of this; PET-CT is used when the CT findings are equivocal or when a metastatic deposit would change the plan.
- Is there occult peritoneal disease? Small deposits on the peritoneum can be invisible on any scan. Staging laparoscopy — a short keyhole look before committing to an operation — finds them in a proportion of patients with otherwise resectable disease and saves an unnecessary laparotomy.
The output of staging is not just a stage number. It is the resectability category, and it should be written down explicitly, because that is what the treatment plan is built on and what makes a second opinion meaningful.
How resectability is judged
Resectability in pancreatic cancer is a statement about the plane between the tumour and the vessels, and it is expressed in four categories rather than as a stage:
- Resectable — a clear fat plane between the tumour and the superior mesenteric artery and coeliac axis, with the portal vein clear or only touching it. Surgery first, then chemotherapy.
- Borderline resectable — short-segment abutment or narrowing of the portal or superior mesenteric vein that can be resected and reconstructed, or abutment of an artery without encasement. Chemotherapy first, then re-image and reconsider surgery.
- Locally advanced — the tumour encircles a major artery, so a margin-negative removal is not achievable. Systemic treatment with or without radiotherapy, and the possibility of surgery is reviewed if the tumour regresses away from the artery.
- Metastatic — spread beyond the pancreas. Surgery on the primary tumour does not improve the outcome in this situation, and treatment is systemic.
Because the judgement is made from images and is not always clear-cut, the most useful thing a patient can do is have the CT reviewed where pancreatic resections are performed routinely. Borderline and locally advanced are decided by millimetres and by interpretation, and the treatment pathway that follows from one or the other is entirely different.
Arranging the work-up from abroad
Nothing in the pancreatic work-up needs to be repeated unnecessarily, and most of it can be reviewed remotely before any travel is considered. What matters is that the right material is sent, because a pancreatic diagnosis cannot be reconstructed from a summary letter.
- The CT on disc, in DICOM format rather than as images in a PDF, with the report if available. This is the single most important item.
- The MRI or MRCP if one was done, and any PET-CT.
- The endoscopy and cytology reports, including the exact wording of the cytology conclusion — "atypical", "suspicious" and "positive for adenocarcinoma" mean different things.
- Blood results, including CA19-9, bilirubin, liver enzymes and HbA1c, with the dates they were taken.
- A list of current medication, particularly anticoagulants, diabetes treatment and any stents that have been placed.
From those items the team can usually state which category the tumour falls into, whether treatment should begin with chemotherapy or with surgery, and what further tests — if any — are worth doing in China. Where an up-to-date pancreatic protocol CT is genuinely needed, it can be arranged quickly, but it should be a decision made with the images already reviewed rather than a routine first step.